Company Zalicus Inc Nasdaq
Equities
US98887C1053
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
Business Summary
Sales per Business
USD in Million | 2014 | Weight | 2015 | Weight | Delta |
---|---|---|---|---|---|
Biopharmaceutical
100.0
%
| 0 | 100.0 % | 1 | 100.0 % | +17,425.00% |
Sales per region
USD in Million | 2014 | Weight | 2015 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 0 | 100.0 % | 1 | 100.0 % | +17,425.00% |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 26,184,349 | 26,184,349 ( 100.00 %) | 0 | 100.00 % |
Company contact information
EPIRUS Biopharmaceuticals, Inc.
699 Boylston Street 8th floor
02116, Boston
+617-600-3497
Sector
1st Jan change | Capi. | |
---|---|---|
+25.69% | 48.09B | |
+46.90% | 40.62B | |
-3.46% | 40.43B | |
-6.20% | 28.36B | |
+9.17% | 24.89B | |
-20.42% | 19.01B | |
+28.07% | 12.09B | |
+0.17% | 11.88B | |
-1.24% | 11.8B |
- Stock Market
- Equities
- EPRSQ Stock
- Stock
- Company Zalicus Inc